Mizuho Securities Reiterates Neutral as Quest Diagnostics (DGX) Announces Optum Collaboration

September 13, 2016 9:18 AM EDT
Get Alerts DGX Hot Sheet
Price: $91.07 +0.08%

Rating Summary:
    10 Buy, 19 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade DGX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities reiterated a Neutral rating and $86.00 price target on Quest Diagnostics (NYSE: DGX) following announced collaboration with Optum.

Analyst Ann Hynes commented, "DGX and Optum announced this morning a wide-ranging, long-term relationship that includes 1) A revenue cycle collaboration where DGX's revenue cycle management (RCM) operations and its 2,400 employees will become part of Optum360 2) DGX will become Optum’s primary partner for member biometric screening services that Optum provides and 3) the companies will work to increase the use of diagnostic information services, such as data analytics, population health insights and connectivity solutions."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $82.27 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment